Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 2, 2010, Pages 140-146

  Tziomalos, K ^a   Athyros, V G ^b   Karagiannis, A ^b   Mikhailidis, D P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Endothelial dysfunction; Lifestyle measures; Metabolic syndrome; Metformin; Statins

Indexed keywords

BIOLOGICAL MARKER; CARDIOVASCULAR AGENT;

BARIATRIC SURGERY; DRUG EFFECT; HEMODYNAMICS; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

BARIATRIC SURGERY; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 75349088914     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.08.006     Document Type: Review

References (60)

1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
2. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 (2005) 2745-2749
3. Grundy S.M. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28 (2008) 629-636
4. Athyros V.G., Ganotakis E.S., Elisaf M., and Mikhailidis D.P. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 21 (2005) 1157-1159
5. Ford E.S., Li C., and Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31 (2008) 1898-1904
6. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
7. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
8. Kullo I.J., and Malik A.R. Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol 49 (2007) 1413-1426
9. Kim J.A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
10. Rossi R., Cioni E., Nuzzo A., Origliani G., and Modena M.G. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 28 (2005) 702-707
11. Perticone F., Maio R., Sciacqua A., Andreozzi F., Iemma G., Perticone M., et al. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 57 (2008) 167-171
12. Benjamin E.J., Larson M.G., Keyes M.J., Mitchell G.F., Vasan R.S., Keaney Jr. J.F., et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 109 (2004) 613-619
13. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R., et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35 (1992) 771-776
14. Brook R.D., Bard R.L., Rubenfire M., Ridker P.M., and Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 88 (2001) 1264-1269
15. Lupattelli G., Lombardini R., Schillaci G., Ciuffetti G., Marchesi S., Siepi D., et al. Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am Heart J 140 (2000) 521-526
16. Kuvin J.T., Patel A.R., Sidhu M., Rand W.M., Sliney K.A., Pandian N.G., et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol 92 (2003) 275-279
17. Deanfield J.E., Halcox J.P., and Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007) 1285-1295
18. Barac A., Campia U., and Panza J.A. Methods for evaluating endothelial function in humans. Hypertension 49 (2007) 748-760
19. Festa A., D'Agostino Jr. R., Mykkanen L., Tracy R.P., Zaccaro D.J., Hales C.N., et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19 (1999) 562-568
20. Potter van Loon B.J., Kluft C., Radder J.K., Blankenstein M.A., and Meinders A.E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42 (1993) 945-949
21. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32 (1989) 219-226
22. Esposito K., Ciotola M., Carleo D., Schisano B., Saccomanno F., Sasso F.C., et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 (2006) 1071-1076
23. Dell'Omo G., Penno G., Pucci L., Mariani M., Del P.S., and Pedrinelli R. Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis 172 (2004) 383-389
24. Hamburg N.M., Larson M.G., Vita J.A., Vasan R.S., Keyes M.J., Widlansky M.E., et al. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 101 (2008) 82-88
25. Lteif A.A., Han K., and Mather K.J. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112 (2005) 32-38
26. Bahia L., Aguiar L.G., Villela N., Bottino D., Godoy-Matos A.F., Geloneze B., et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 61 (2006) 433-440
27. Bahia L., Aguiar L.G., Villela N., Bottino D., Godoy-Matos A.F., Geloneze B., et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 195 (2007) 138-146
28. Lind L. Endothelium-dependent vasodilation, insulin resistance and the metabolic syndrome in an elderly cohort: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 196 (2008) 795-802
29. Title L.M., Lonn E., Charbonneau F., Fung M., Mather K.J., Verma S., et al. Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. Vasc Med 13 (2008) 263-270
30. Blanco-Colio L.M., Martin-Ventura J.L., de T.E., Farsang C., Gaw A., Gensini G., et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 153 (2007) 881-888
31. Anand S.S., Yi Q., Gerstein H., Lonn E., Jacobs R., Vuksan V., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 (2003) 420-425
32. You T., Nicklas B.J., Ding J., Penninx B.W., Goodpaster B.H., Bauer D.C., et al. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci 63 (2008) 414-419
33. Mertens I., Verrijken A., Michiels J.J., Van der P.M., Ruige J.B., and Van Gaal L.F. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 30 (2006) 1308-1314
34. Piatti P.M., Monti L.D., Conti M., Baruffaldi L., Galli L., Phan C.V., et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45 (1996) 316-321
35. Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A., et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 257 (2005) 454-460
36. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., Fonseca V., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140 (2004) 167-174
37. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
38. Panza J.A., Quyyumi A.A., Brush Jr. J.E., and Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323 (1990) 22-27
39. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27 (1996) 567-574
40. Rodriguez C.J., Miyake Y., Grahame-Clarke C., Di Tullio M.R., Sciacca R.R., Boden-Albala B., et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol 96 (2005) 1273-1277
41. Vehkavaara S., Seppala-Lindroos A., Westerbacka J., Groop P.H., and Yki-Jarvinen H. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 22 (1999) 2055-2060
42. Henry R.M., Ferreira I., Kostense P.J., Dekker J.M., Nijpels G., Heine R.J., et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis 174 (2004) 49-56
43. Beckman J.A., Goldfine A.B., Gordon M.B., and Creager M.A. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103 (2001) 1618-1623
44. Title L.M., Cummings P.M., Giddens K., and Nassar B.A. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 36 (2000) 2185-2191
45. Houben A.J., Schaper N.C., de Haan C.H., Huvers F.C., Slaaf D.W., de Leeuw P.W., et al. Local 24-h hyperglycemia does not affect endothelium-dependent or -independent vasoreactivity in humans. Am J Physiol 270 (1996) H2014-H2020
46. Perticone F., Ceravolo R., Candigliota M., Ventura G., Iacopino S., Sinopoli F., et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50 (2001) 159-165
47. Arcaro G., Zamboni M., Rossi L., Turcato E., Covi G., Armellini F., et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 23 (1999) 936-942
48. Lupattelli G., Marchesi S., Roscini A.R., Siepi D., Gemelli F., Pirro M., et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am J Cardiol 90 (2002) 648-650
49. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., and Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38 (2001) 111-116
50. Schnell G.B., Robertson A., Houston D., Malley L., and Anderson T.J. Impaired brachial artery endothelial function is not predicted by elevated triglycerides. J Am Coll Cardiol 33 (1999) 2038-2043
51. Chowienczyk P.J., Watts G.F., Wierzbicki A.S., Cockcroft J.R., Brett S.E., and Ritter J.M. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol 29 (1997) 964-968
52. Ghiadoni L., Penno G., Giannarelli C., Plantinga Y., Bernardini M., Pucci L., et al. Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension 51 (2008) 440-445
53. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
54. Sierra-Johnson J., Johnson B.D., Allison T.G., Bailey K.R., Schwartz G.L., and Turner S.T. Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care 29 (2006) 668-672
55. Hivert M.F., Sullivan L.M., Fox C.S., Nathan D.M., D'Agostino Sr. R.B., Wilson P.W., et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 93 (2008) 3165-3172
56. Steinberg H.O., Brechtel G., Johnson A., Fineberg N., and Baron A.D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94 (1994) 1172-1179
57. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97 (1996) 2601-2610
58. Laakso M., Edelman S.V., Brechtel G., and Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85 (1990) 1844-1852
59. Arcaro G., Cretti A., Balzano S., Lechi A., Muggeo M., Bonora E., et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105 (2002) 576-582
60. Cardillo C., Nambi S.S., Kilcoyne C.M., Choucair W.K., Katz A., Quon M.J., et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100 (1999) 820-825